Axial light loss of monocytes as a readily available prognostic biomarker in patients with suspected infection at the emergency department

Titus A. P. de Hond, Wout J. Hamelink, Mark C. H. de Groot, Imo E. Hoefer, Jan Jelrik Oosterheert, Saskia Haitjema, Karin A. H. Kaasjager

1 Department of Internal Medicine and Acute Medicine, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands, 2 Central Diagnostic Laboratory, Division Laboratory, Pharmacy and Biomedical Genetics, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands, 3 Department of Internal Medicine and Infectious Diseases, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands

Abstract

Objectives
To evaluate the prognostic value of the coefficient of variance of axial light loss of monocytes (cv-ALL of monocytes) for adverse clinical outcomes in patients suspected of infection in the emergency department (ED).

Methods
We performed an observational, retrospective monocenter study including all medical patients ≥18 years admitted to the ED between September 2016 and June 2019 with suspected infection. Adverse clinical outcomes included 30-day mortality and ICU/MCU admission <3 days after presentation. We determined the additional value of monocyte cv-ALL and compared to frequently used clinical prediction scores (SIRS, qSOFA, MEWS). Next, we developed a clinical model with routinely available parameters at the ED, including cv-ALL of monocytes.

Results
A total of 3526 of patients were included. The OR for cv-ALL of monocytes alone was 2.21 (1.98–2.47) for 30-day mortality and 2.07 (1.86–2.29) for ICU/MCU admission <3 days after ED presentation. When cv-ALL of monocytes was combined with a clinical score, the prognostic accuracy increased significantly for all tested scores (SIRS, qSOFA, MEWS). The maximum AUC for a model with routinely available parameters at the ED was 0.81 to predict 30-day mortality and 0.81 for ICU/MCU admission.

Conclusions
Cv-ALL of monocytes is a readily available biomarker that is useful as prognostic marker to predict 30-day mortality. Furthermore, it can be used to improve routine prediction of adverse clinical outcomes at the ED.
Clinical trial registration
Registered in the Dutch Trial Register (NTR) und number 6916.

1. Introduction
Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection [1]. It is a clinical syndrome that is known to have high morbidity and mortality rates [2, 3]. Unfortunately, no accurate diagnostic tools are available for early recognition of sepsis [4–7]. Clinical prediction scores (e.g. SIRS, (q)SOFA or Modified Early Warning Score (MEWS)) have been developed for recognition of severely ill patients in an Emergency Department (ED) setting [1, 4, 8–10] but poorly predict adverse clinical outcomes [11–14]. In addition, these scores consist of different patient characteristics that need to be collected manually and processed in the electronic health record (EHR) system to perform optimally. Moreover, scores such as the MEWS were not specifically developed in the context of sepsis, but rather to predict outcome in a range of critically ill patients [11, 15]. Therefore, there is a continuous need for easy, accurate and cheap accessible biomarkers for prediction of adverse clinical outcomes in sepsis patients, especially early in the course of the disease. Recently, numerous biomarkers have been identified, but these are mostly costly and therefore complicate the chase for value-based healthcare.

Leukocytes play a key role in the inflammatory host response to infection [16, 17] and are therefore used as biomarker for the disease [18]. Nevertheless, leukocytes are nonspecific and consist of multiple cell subsets [17, 19] that may be more specific and more accurate biomarkers for sepsis [17]. Specifically monocytes, as part of the innate immune system, play a crucial role in the very early stage of sepsis [20, 21]. In early stages of sepsis monocytes are activated and undergo morphological changes [21, 22] that may be useful for early identification of the disease. Recently, Monocyte Distribution Width (MDW) was suggested as an early sepsis indicator [22–27]. A downside to MDW as a biomarker is the requirement of a specific costly analyzer [22]. Another approach to calculate the variety in monocyte size uses the flow cytometry principle within existing hematology analyzers to assess leukocyte subsets. The axial light loss (ALL) or ‘shadow’ that is routinely obtained as a cell passes the laser light inside the machine during such a measurement can be seen as a proxy of cell size. In raw hematology data ALLs are available as means with accompanying coefficients for different subsets of leukocytes. Coefficient of variance of axial light loss of monocytes (cv-ALL of monocytes) can be seen as a way to express variety in monocytic volumetric size, and is thereby very much comparable to MDW.

Therefore, we used readily available cv-ALL of monocytes to study monocyte characteristics as a biomarker for clinical outcome. We hypothesized that cv-ALL of monocytes is a valuable biomarker to predict clinical adverse outcomes in patients that are suspected of an infection at the ED.

2. Methods
2.1 Study design
We performed an observational retrospective cohort study on data from the SPACE-cohort (SePsis in the Acutely ill patients in the Emergency department) [28] that was collected between September 2016 and September 2019. The SPACE-cohort includes all patients with suspected infection presenting in the ED of the University Medical Centre Utrecht (UMCU)
that fulfill the following 2 inclusion criteria: ≥18 years, and presenting for the internal medicine department or one of its subspecialities. No other in- or exclusion criteria are used.

All patients in the SPACE-cohort were assessed for the presence of sepsis. If sepsis was suspected a sepsis care pathway was initiated, resulting in protocolized care. Non-septic patients received standard of care treatment according to their clinical situation. The SPACE-cohort was reviewed and approved by the Medical Ethical Committee of the UMCU under number 16/594 and registered in the Dutch Trial Register (NTR) under number 6916.

2.2 Data collection
The treating physician at the ED is always asked by the EHR system whether the patient is suspected of an infection and whether it could be sepsis in our center. If both questions are answered positively, the system automatically calculates the SIRS and qSOFA scores using the first set of vital parameters obtained during the ED visit. If no such parameters are available in the system, lacking parameters can be added manually. When at least one of the scores is abnormal, the physician is alerted by a screen warning message. These patients were automatically included in the SPACE cohort.

As secondary quality check for completeness of the SPACE cohort, independent trained clinicians screened all patient records of ED visits for the suspicion of infection and/or sepsis if registration via the clinical pathway was absent. If an infectious cause was mentioned in the differential diagnosis, patients received antibiotics, or bacterial cultures were taken these patients were considered to be suspected of infection and were also included in the SPACE-cohort.

For all included patients, data concerning demographics, vital parameters, antibiotics, comorbidities, and outcome was collected manually and supplemented with automated queries for laboratory variables to calculate cv-ALL of monocytes. Data on vital parameters included all parameters to calculate clinical prediction scores (SIRS, qSOFA, MEWS) and follow-up data on morbidity and mortality included microbiological diagnostics, chosen treatment, hospitalization, and length of stay). Charlson Comorbidity Index (CCI) was used for the collection of comorbidities [29].

2.3 Biochemical parameters
Standardized blood draw was performed at the ED including a complete blood count (CBC). In the UMC Utrecht, raw data including the full optical parameters of each measured individual blood cell is extracted automatically from the hematological analyzer (Abbott CELL-DYN Sapphire) and stored into the Utrecht Patient Oriented Database (UPOD). The structure and content of UPOD have been described in more detail elsewhere [30]. From this raw data we extracted the cv-ALL of monocytes.

2.4 Outcomes
The primary outcome of this study was 30-day all-cause mortality [31, 32] and secondary endpoints were Medium Care Unit (MCU) or Intensive Care Unit (ICU) admission <3 days after ED presentation. For the secondary outcome, all patients with an ICU-restrictive policy were excluded.

2.5 Statistical analyses
Normally distributed continuous data are expressed as a mean with standard deviation (SD). Non-parametric data are shown as median and interquartile range (IQR). Student’s t test was used to compare normally distributed continuous parameters, while a Mann Whitney U test was used for non-parametric continuous variables. Categorical variables were compared using
Chi-Square or Fisher’s exact test, depending on variable size. We used a predictive mean matching multiple imputation approach for missing values. All included vital, laboratory and outcome parameters that were used in our analyses were used. Concerning data points on laboratory variables, hospital admission, and clinical course, all used parameters had missing data <1%. This was also the case for all used vital parameters, except for respiratory rate (missing 25.8%). No data on demographics were missing.

We studied the association between cv-ALL of monocytes and outcomes using binary logistic regression models. First, we compared the predictive value of cv-ALL of monocytes to frequently used clinical prediction scores (SIRS, qSOFA, MEWS). The optimal cut-off point for cv-ALL of monocytes was calculated via Youden’s statistic. Next, we tested the additional value of cv-ALL of monocytes on top of these scores. We assessed additional value using likelihood ratio tests. Finally, using stepwise regression via backward selection, we combined all individual parameters from the clinical scores, patient characteristics, and cv-ALL of monocytes to come up with a clinical model with easily accessible parameters. Prognostic accuracy was evaluated by receiver operating characteristic (ROC) curve analyses and reported as area under the curve (AUC) with 95% confidence intervals. Calibration curves were constructed with R Statistical Software, version 4.0.3. The following packages were used: haven, tidyverse, and rms. IBM SPSS Statistics version 26.0 was used for all other analyses and p-values below 0.05 were considered statistically significant.

3. Results

3.1 Patient characteristics

A total of 3526 patients were enrolled. Table 1 shows the baseline characteristics of the cohort. Patients were on average 61.0 years old (53.4% male). Median of cv-ALL of monocytes in the whole cohort was 0.077 (IQR 0.070–0.088). Cv-ALL of monocytes was associated with disease severity (S1 and S2 Figs). The magnitude of cv-ALL of monocytes increases in sicker patients (S1 Fig). The percentage of patients with a high cv-ALL of monocytes measurement increased if SIRS, qSOFA or MEWS get higher (S2 Fig). Additionally, we hypothesized that cv-ALL of monocytes might differ between immunocompromised and non-immunocompromised patients and indeed, there was a significant difference between these two groups (S3 Fig).

3.2 Primary outcome

The overall 30-day mortality was 6.3% (222/3526 patients). The median cv-ALL of monocytes in survivors and non-survivors was 0.077 (IQR 0.070–0.088) vs 0.084 (IQR 0.073–0.098), p <0.001. The optimal cut-off point to predict 30-day mortality was 0.085. This dichotomization resulted in an OR of 2.21 (95% CI 1.98–2.47, Table 2). Based on the likelihood ratio tests, cv-ALL of monocytes had an additional predictive value to every clinical prediction score (Fig 1A, Table 3). The best multivariable logistic regression model contained cv-ALL of monocytes, age, sex, CCI, respiratory rate, systolic blood pressure, Glasgow Coma Scale, heart rate, white blood cell count and body temperature as independent factors associated with 30-day mortality. The corresponding ROC curves are shown in Fig 2A, with an AUC for this model of 0.81. Calibration curve of the optimal model is shown in S4 Fig with $R^2$ of 0.209 and Brier score of 0.054.

3.3 Secondary outcome

Within 3 days after ED visit, 8.6% (303/3526 patients) were admitted to MCU and/or ICU. The optimal cut-off point for cv-ALL of monocytes was 0.088, corresponding with an OR of
Table 1. Baseline table of the SPACE population.

|                        | Total (n = 3526) | Survivors (n = 3304) | Non-survivors (n = 222) | P-value |
|------------------------|------------------|----------------------|-------------------------|---------|
| **Demographic**        |                  |                      |                         |         |
| Age–yr–median (IQR)    | 61.0 (48.0–70.0) | 61.0 (46.0–70.0)     | 68.0 (59.0–75.0)        | <0.001  |
| Sex, male (%)          | 1884 (53.4%)     | 1735 (52.5%)         | 149 (67.1%)             | <0.001  |
| CCI (≥ 5) (%)          | 1683 (47.7%)     | 1503 (45.5%)         | 180 (81.1%)             | <0.001  |
| **Specialties**        |                  |                      |                         |         |
| Internal medicine (%)  | 1088 (30.9%)     | 1029 (31.1%)         | 59 (26.6%)              |         |
| Nephrology (%)         | 571 (16.2%)      | 559 (16.9%)          | 12 (5.4%)               |         |
| Oncology (%)           | 615 (17.4%)      | 536 (16.2%)          | 79 (35.6%)              |         |
| Hematology (%)         | 574 (16.3%)      | 531 (16.1%)          | 43 (19.4%)              |         |
| Rheumatology (%)       | 207 (5.9%)       | 200 (6.1%)           | 7 (3.2%)                |         |
| Endocrinology (%)      | 124 (3.5%)       | 123 (3.7%)           | 1 (0.5)                 |         |
| Infectious diseases (%)| 74 (2.1%)        | 73 (2.2%)            | 1 (0.5)                 |         |
| Other (%)              | 273 (7.7%)       | 253 (7.7%)           | 20 (9.0)                |         |
| **Clinical scores**    |                  |                      |                         |         |
| SIRS score ≥2 (%)      | 2194 (62.2%)     | 2025 (61.3%)         | 169 (76.1%)             | <0.001  |
| qSOFA score ≥2 (%)     | 195 (5.5%)       | 154 (4.7)            | 41 (18.5%)              | <0.001  |
| MEWS ≥5 (%)            | 498 (14.1%)      | 425 (12.9%)          | 73 (32.9%)              | <0.001  |
| **Timing of antibiotics** |             |                      |                         |         |
| No antibiotics         | 2136 (60.6%)     | 2051 (62.1%)         | 85 (38.3%)              |         |
| <1 hour                | 148 (4.2%)       | 129 (3.9%)           | 19 (8.6%)               |         |
| 1–3 hours              | 568 (16.1%)      | 515 (15.6%)          | 53 (23.9%)              |         |
| >3 hours               | 674 (19.1%)      | 609 (18.4%)          | 65 (29.3%)              |         |
| **Clinical course**    |                  |                      |                         |         |
| Hospital admission (%) | 2307 (65.4%)     | 2113 (64.0%)         | 194 (87.4%)             | <0.001  |
| Length of stay–days–median (IQR) | 4.7 (2.7–8.7) | 4.7 (2.7–8.5) | 5.6 (2.5–12.7) | 0.069  |
| **Cv-ALL of monocytes** |                  |                      |                         |         |
| Median cv-ALL of monocytes (IQR) | 0.077 (0.070–0.088) | 0.077 (0.070–0.088) | 0.084 (0.073–0.098) | <0.001 |

CCI, Charlson Comorbidity Index; cv-ALL, coefficient of variance of axial light loss

https://doi.org/10.1371/journal.pone.0270858.t001

Table 2. Univariate logistic regression for 30-day mortality.

| Predictor                  | OR (95% CI) | p-Value |
|---------------------------|------------|---------|
| **30-day mortality**      |            |         |
| cv-ALL (≥0.085)           | 2.21 (1.98–2.47) | <0.001 |
| SIRS (≥2)                 | 1.88 (1.65–2.14) | <0.001 |
| qSOFA (≥2)                | 4.57 (3.932–5.32) | <0.001 |
| MEWS (≥5)                 | 3.06 (2.72–3.46) | <0.001 |
| **ICU/MCU admission <3 days** |            |         |
| cv-ALL (≥0.088)           | 2.07 (1.86–2.29) | <0.001 |
| SIRS (≥2)                 | 3.32 (2.89–3.80) | <0.001 |
| qSOFA (≥2)                | 10.10 (8.82–11.56) | <0.001 |
| MEWS (≥5)                 | 5.60 (5.04–6.22) | <0.001 |

cv-ALL, Coefficient of Variance Axial Light Loss; qSOFA, quick Sequential Organ Failure Assessment; OR, odds ratio; CI, confidence interval.

https://doi.org/10.1371/journal.pone.0270858.t002
The AUC for cv-ALL of monocytes was lower than for SIRS, qSOFA, and MEWS (AUC 0.60 vs 0.61 vs 0.62 vs 0.66 respectively, Fig 1B, Table 3). Again, cv-ALL of monocytes added significantly to the model performance of each clinical score (Table 3). In multivariable regression analysis cv-ALL of monocytes, age, sex, CCI, respiratory rate, systolic blood pressure, Glasgow Coma Scale, heart rate, white blood count and body temperature were independent predictors for ICU/MCU admission <3 days after ED presentation. The maximum AUC for this model was 0.81 (Fig 2B), with calibration curve shown in S4 Fig ($R^2 = 0.220$; Brier score = 0.070). Unlike for our primary outcome, CCI was negatively correlated with ICU/MCU admission, meaning a higher CCI was associated with a lower chance of being admitted to the ICU/MCU <3 days.

### Table 3. AUC of clinical prediction scores with(out) cv-ALL of monocytes.

| Predictor                   | AUC  | LRT       |
|-----------------------------|------|-----------|
| **30-day mortality**        |      |           |
| cv-ALL                      | 0.61 | -         |
| SIRS ($\geq 2$)             | 0.57 |           |
| SIRS + cv-ALL               | 0.62 | <0.001    |
| qSOFA ($\geq 2$)            | 0.57 |           |
| qSOFA + cv-ALL              | 0.64 | <0.001    |
| MEWS ($\geq 5$)             | 0.60 |           |
| MEWS + cv-ALL               | 0.65 | <0.001    |
| **ICU/MCU admission <3 days** |      |           |
| cv-ALL                      | 0.60 | -         |
| SIRS ($\geq 2$)             | 0.61 |           |
| SIRS + cv-ALL               | 0.66 | <0.001    |
| qSOFA ($\geq 2$)            | 0.62 |           |
| qSOFA + cv-ALL              | 0.66 | <0.001    |
| MEWS ($\geq 5$)             | 0.66 |           |
| MEWS + cv-ALL               | 0.70 | <0.001    |

cv-ALL, Coefficient of Variance Axial Light Loss; LRT, Likelihood Ratio Test; qSOFA, quick Sequential Organ Failure Assessment; OR, odds ratio; CI, confidence interval.

https://doi.org/10.1371/journal.pone.0270858.t003
4. Discussion

This is the first study that investigated cv-ALL of monocytes as a biomarker to predict adverse clinical outcomes in patients suspected of an infection at the ED. Our results show that cv-ALL of monocytes could be a usable predictor for both 30-day mortality and MCU/ICU admission for patients that present at the ED and are suspected of an infection. Moreover, cv-ALL of monocytes has additional value to predict mortality and MCU/ICU requirements to the commonly used clinical prediction scores.

Recently, there have been numerous publications on MDW in the context of sepsis [22–27]. However, all previous MDW studies investigated the diagnostic value of MDW for sepsis, rather than its prognostic value. Therefore, it is hard to compare these diagnostic MDW studies with our prognostic study on the cv-ALL of monocytes. A careful comparison can be made, since patients with the diagnosis sepsis are known to have higher adverse outcome rates than patients with less severe conditions [3, 33, 34]. In previous studies, MDW was found able to distinguish SIRS from sepsis-2 [22, 23] as well as to diagnose sepsis based on the sepsis-3 definition with AUCs ranging from 0.73–0.87 [24–26]. In line with this, we found that high values for cv-ALL of monocytes correlate with an increasing risk for adverse clinical outcomes. Additionally, MDW elevation was correlated with infection severity [25, 35] and low values of MDW had strong negative predictive values in the context of sepsis (87–97%, [25–27]). This is similar to our study, which shows that clinically sicker patients have higher cv-ALL of monocytes values.

There are several reasons why cv-ALL of monocytes should be preferred above MDW. Cv-ALL of monocytes is readily available and easily accessible as it can be extracted from a routine hematological analyzer. Consequently, we did not have to perform an extra lab test or buy an extra machine. This implicates major clinical advantages compared to measuring MDW: cv-ALL of monocytes does not require technical knowledge or laboratory space, and is cheaper. Since the essence of the test is so similar to the measurement of MDW and since our results point in the same direction to previous results, it is likely that cv-ALL of monocytes can replace MDW.

Our study has some limitations. First, we imputed missing data of some of the variables, up to 25% for respiratory rate. This may have influenced the performance of our models. We acknowledge that these data may not be missing completely at random. Yet, because severely ill patients have more complete EHR records [36], it is likely that in less severely ill patients more imputation was required. Therefore, undocumented abnormal respiratory rates in less
severely ill patients might be imputed within the normal range. Because of this, we only believe that imputation could have led to underestimation of our results. Second, the study was performed at the UMCU, a large tertiary hospital that is known for its relatively large population of immunocompromised patients. In a subanalysis, cv-ALL of monocytes differed significantly between immunocompromised and non-immunocompromised patients, indicating that immunosuppression affects cv-ALL of monocyte values. Nonetheless, even in this academic population cv-ALL of monocytes appears to be a predictor for adverse clinical outcomes. At last, we show that multivariate models can achieve good AUCs to predict outcome. However, both calibration plots show overestimation in high risk patients, which might be due to the low number of patients with high prediction scores. Therefore, except for ruling out, these models would not be suitable for clinical implementation yet.

There are a few specific strengths to this study. First, current sepsis guidelines advise using qSOFA in the ED setting to predict clinical outcome as opposed to using it as a diagnostic tool [1, 13]. Adding this to the absence of a gold standard to diagnose sepsis at the ED, we decided upon a prognostic study with well-defined outcome measurements rather than a diagnostic design. Moreover, the SPACE-cohort has a well-defined and clinically relevant patient domain, namely all patients at the ED that are suspected of an infection. The heterogeneity resulting from this cohort might explain the relatively low performances of the clinical scores, when compared to other literature [11, 14].

5. Conclusion

This study shows that cv-ALL of monocytes is a valuable predictor for 30-day mortality and MCU/ICU requirement <3 days after ED visit in patients suspected of infection at the ED. The clinical performance is likely to be equal to MDW. Nevertheless, cv-ALL of monocytes has multiple practical advantages compared to MDW, making cv-ALL of monocytes more preferable.

Supporting information

S1 Fig. Cv-ALL of monocytes is associated with disease severity. SIRS (A), qSOFA (B), and MEWS (C) score and height of cv-ALL of monocytes is shown. A one-way ANOVA was performed to test group differences. Significance testing was done by Tukey’s test. **p < 0.01, ***p < 0.001. (TIF)

S2 Fig. High cv-ALL of monocytes percentage for SIRS (A), qSOFA (B), and MEWS (C) scores. High cv-ALL of monocytes was defined as the cut-off value for our clinical model to predict 30-day mortality (0.085). P-values were calculated with a X-square test. (TIF)

S3 Fig. Cv-ALL of monocytes in non-immunocompromised (-) and immunocompromised (+) patients. Cv-ALL of monocytes differed significantly between these two groups. P-value was calculated by a Mann-Whitney U test. (TIF)

S4 Fig. Optimal model calibration plots for 30-day mortality (A) and ICU/MCU admission <3 days (B). The dashed line shows the calibration plot for the optimal models. The model for 30-day mortality has R² of 0.209 and Brier score of 0.054, while the model for ICU/MCU admission <3 days shows R² of 0.220 and Brier score of 0.070. (TIF)
Author Contributions

Conceptualization: Titus A. P. de Hond, Imo E. Hoefer, Saskia Haitjema, Karin A. H. Kaasjager.

Data curation: Titus A. P. de Hond, Wout J. Hamelink, Mark C. H. de Groot.

Formal analysis: Titus A. P. de Hond, Wout J. Hamelink.

Investigation: Titus A. P. de Hond, Mark C. H. de Groot, Saskia Haitjema.

Methodology: Titus A. P. de Hond.

Project administration: Titus A. P. de Hond.

Supervision: Jan Jelrik Oosterheert, Karin A. H. Kaasjager.

Writing – original draft: Titus A. P. de Hond, Wout J. Hamelink.

Writing – review & editing: Titus A. P. de Hond, Imo E. Hoefer, Jan Jelrik Oosterheert, Saskia Haitjema, Karin A. H. Kaasjager.

References

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801–10. Epub 2016/02/24. https://doi.org/10.1001/jama.2016.0287 PMID: 26903338; PubMed Central PMCID: PMC4968574.

2. Fleischmann C, Thomas-Rueddel DO, Hartmann M, Hartog CS, Welle T, Heublein S, et al. Hospital Incidence and Mortality Rates of Sepsis. Dtsch Arztebl Int. 2016; 113(10):159–66. Epub 2016/03/25. https://doi.org/10.3238/arztebl.2016.0159 PMID: 27010950; PubMed Central PMCID: PMC4814768.

3. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kieffan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet. 2020; 395(10219):200–11. Epub 2020/01/20. https://doi.org/10.1016/S0140-6736(19)32989-7 PMID: 31954465; PubMed Central PMCID: PMC6970225.

4. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992; 101(6):1644–55. Epub 1992/06/01. https://doi.org/10.1378/chest.101.6.1644 PMID: 1303622

5. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003; 31(4):1250–6. Epub 2003/04/12. https://doi.org/10.1097/01.CCM.0000050454.01978.3B PMID: 12682500.

6. Churpek MM, Zadravecz FJ, Winslow C, Howell MD, Edelson DP. Incidence and Prognostic Value of the Systemic Inflammatory Response Syndrome and Organ Dysfunctions in Ward Patients. Am J Respir Crit Care Med. 2015; 192(8):958–64. Epub 2015/07/15. https://doi.org/10.1164/rcrm.201502-0275OC PMID: 26158402; PubMed Central PMCID: PMC4642209.

7. Kaukonen KM, Bailey M, Pilcher D, Cooper DJ, Bellomo R. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med, 2015; 372(17):1629–38. Epub 2015/03/18. https://doi.org/10.1056/NEJMoa1415236 PMID: 25776936.

8. Corfield AR, Lees F, Zealley I, Houston G, Dickie S, Ward K, et al. Utility of a single early warning score in patients with sepsis in the emergency department. Emerg Med J. 2014; 31(6):482–7. Epub 2013/03/12. https://doi.org/10.1136/emergmed-2012-202186 PMID: 23475607.

9. Subbe CP, Kruger M, Rutherford P, Gemmel L. Validation of a modified Early Warning Score in medical admissions. QJM. 2001; 94(10):521–6. Epub 2001/10/06. https://doi.org/10.1093/qjmed/94.10.521 PMID: 11588210.

10. Morgan RJM WF, Wright MM. An early warning scoring system for detecting developing critical illness. Clin Intensive Care. 1997; 8:100.

11. Goulden R, Hoyle MC, Monis J, Raitlon D, Riley V, Martin P, et al. qSOFA, SIRS and NEWS for predicting inhospital mortality and ICU admission in emergency admissions treated as sepsis. Emerg Med J. 2018; 35(6):345–9. Epub 2018/02/23. https://doi.org/10.1136/emermed-2017-207120 PMID: 29467173.
Axial light loss of monocytes as biomarker in patients with suspected infection at the emergency department

12. van der Woude SW, van Doormaal FF, Hutten BA, F JN, Holleman F. Classifying sepsis patients in the emergency department using SIRS, qSOFA or MEWS. Neth J Med. 2018; 76(4):158–66. Epub 2018/05/31. PMID: 29845938.

13. Seymour CW, Liu VX, Iwashyna TJ, Brunekhorst FM, Rea TD, Scherag A, et al. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):762–74. Epub 2016/02/24. https://doi.org/10.1001/jama.2016.0288 PMID: 26903335; PubMed Central PMCID: PMC5433435.

14. Haydar S, Spanier M, Weems P, Wood S, Strout T. Comparison of qSOFA score and SIRS criteria as screening mechanisms for emergency department sepsis. Am J Emerg Med. 2017; 35(11):1730–3. Epub 2017/07/18. https://doi.org/10.1016/j.ajem.2017.07.001 PMID: 28712645.

15. McGinley A, Pearse RM. A national early warning score for acutely ill patients. BMJ. 2012; 345:e5310. Epub 2012/08/10. https://doi.org/10.1136/bmj.e5310 PMID: 22875955.

16. Ploppa A, Schmidt V, Hientz A, Reutershan J, Haeberle HA, Nohe B. Mechanisms of leukocyte distribution during sepsis: an experimental study on the interdependence of cell activation, shear stress and endothelial injury. Crit Care. 2010; 14(6):R201. Epub 2010/11/10. https://doi.org/10.1186/cc9322 PMID: 21059228; PubMed Central PMCID: PMC3220016.

17. Rimmele T, Payen D, Cantaluppi V, Marshall J, Gomez H, Gomez A, et al. Immune Cell Phenotype and Function in Sepsis. Shock. 2016; 45(3):282–91. Epub 2015/11/04. https://doi.org/10.1097/SHK.0000000000000495 PMID: 26529661; PubMed Central PMCID: PMC4752878.

18. Muller Kobold AC, Tulleken JE, Zijlstra JG, Sluiter W, Hermans J, Kallenberger CG, et al. Leukocyte activation in sepsis; correlations with disease state and mortality. Intensive Care Med. 2000; 26(7):883–92. Epub 2000/09/16. https://doi.org/10.1007/s001340051277 PMID: 10991010.

19. Seigel TA, Cocchi MN, Salciccioli J, Shapiro NI, Howell M, Tang A, et al. Inadequacy of temperature and white blood cell count in predicting bacteremia in patients with suspected infection. J Emerg Med. 2012; 42(3):254–9. Epub 2012/08/03. https://doi.org/10.1016/j.jemermed.2012.05.038 PMID: 22674238.

20. Behnes M, Bertsch T, Lepiorz D, Lang S, Trinkmann F, Brueckmann M, et al. Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment. Crit Care. 2014; 18(5):507. Epub 2014/09/06. https://doi.org/10.1186/s13054-014-0507-z PMID: 25190134; PubMed Central PMCID: PMC4174283.

21. Tak T, van Groenendaal R, Pickkers P, Koenderman L. Monocyte Subsets Are Differentially Lost from the Circulation during Acute Inflammation Induced by Human Experimental Endotoxemia. J Innate Immun. 2017; 9(5):464–74. Epub 2017/06/24. https://doi.org/10.1159/000475665 PMID: 28641299; PubMed Central PMCID: PMC5738874.

22. Crouser ED, Parrillo JE, Seymour C, Angus DC, Bicking K, Tejidor L, et al. Improved Early Detection of Sepsis in the ED With a Novel Monocyte Distribution Width Biomarker. Chest. 2017; 152(1):1951–7. Epub 2020/07/01. https://doi.org/10.1016/j.chest.2020.04.031 PMID: 32391157; PubMed Central PMCID: PMC7201542.

23. Agnello L, Bivona G, Vidal M, Scazzone C, Giglio RV, Iacolino G, et al. Monocyte distribution width (MDW) as a screening tool for sepsis in the Emergency Department. Clin Chem Lab Med. 2020; 58(11):1951–7. Epub 2020/07/01. https://doi.org/10.1515/cclm-2020-0417 PMID: 32598299.

24. Crouser ED, Parrillo JE, Martin GS, Huang DT, Hausfater P, Grigorov I, et al. Monocyte distribution width enhances early sepsis detection in the emergency department beyond SIRS and qSOFA. J Intensive Care. 2020; 8:33. Epub 2020/05/12. https://doi.org/10.1186/s40560-020-00446-3 PMID: 32391157; PubMed Central PMCID: PMC7201542.

25. Pollili E, Sozio F, Frattari A, Persichitti L, Sensi M, Posata R, et al. Comparison of Monocyte Distribution Width (MDW) and Procalcitonin for early recognition of sepsis. PLoS One. 2020; 15(1):e0227300. Epub 2020/01/11. https://doi.org/10.1371/journal.pone.0227300 PMID: 31923207; PubMed Central PMCID: PMC6953886.

26. Crouser ED, Parrillo JE, Seymour CW, Angus DC, Bicking K, Esquerra VG, et al. Monocyte Distribution Width: A Novel Indicator of Sepsis-2 and Sepsis-3 in High-Risk Emergency Department Patients. Crit Care Med. 2019; 47(8):1018–25. Epub 2019/05/21. https://doi.org/10.1097/CCM.0000000000003799 PMID: 31107278; PubMed Central PMCID: PMC6629174.

27. Hausfater P, Robert Boter N, Morales Indiano C, Cancella de Abreu M, Marin AM, Pernet J, et al. Monocyte distribution width (MDW) performance as an early sepsis indicator in the emergency department: comparison with CRP and procalcitonin in a multicenter international European prospective study. Crit Care. 2021; 25(1):227. Epub 2021/07/02. https://doi.org/10.1186/s13054-021-03622-5 PMID: 34193208; PubMed Central PMCID: PMC8247285.

28. Uffen JW, Oomen P, de Regt M, Oosterheert JJ, Kaasjager K. The prognostic value of red blood cell distribution width in patients with suspected infection in the emergency department. BMC Emerg Med.
29. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373–83. Epub 1987/01/01. https://doi.org/10.1016/0021-9681(87)90171-8 PMID: 3558716.

30. ten Berg MJ, Huisman M, van den Bergh PM, Schobben AF, Egberts AC, van Solinge WW. Linking laboratory and medication data: new opportunities for pharmacoepidemiological research. Clin Chem Lab Med. 2007; 45(1):13–9. Epub 2007/01/25. https://doi.org/10.1515/CCLM.2007.009 PMID: 17243908.

31. Brink A, Alsmar J, Verdonschot R, Rood PPM, Zietse R, Lingsma HF, et al. Predicting mortality in patients with suspected sepsis at the Emergency Department; A retrospective cohort study comparing qSOFA, SIRS and National Early Warning Score. PLoS One. 2019; 14(1):e0211133. Epub 2019/01/27. https://doi.org/10.1371/journal.pone.0211133 PMID: 30682104; PubMed Central PMCID: PMC6347138.

32. Sevilla Berrios RA, O’Horo JC, Velagapudi V, Pulido JN. Correlation of left ventricular systolic dysfunction determined by low ejection fraction and 30-day mortality in patients with severe sepsis and septic shock: a systematic review and meta-analysis. J Crit Care. 2014; 29(4):495–9. Epub 2014/04/22. https://doi.org/10.1016/j.jcrc.2014.03.007 PMID: 24746109.

33. Vincent JL. The Clinical Challenge of Sepsis Identification and Monitoring. PLoS Med. 2016; 13(5): e1002022. Epub 2016/05/18. https://doi.org/10.1371/journal.pmed.1002022 PMID: 27187803; PubMed Central PMCID: PMC4871479.

34. Menendez R, Torres A, Reyes S, Zalacain R, Capelastegui A, Aspa J, et al. Initial management of pneumonia and sepsis: factors associated with improved outcome. Eur Respir J. 2012; 39(1):156–62. Epub 2011/08/11. https://doi.org/10.1183/09031936.00188710 PMID: 21828033.

35. Agnello L, Sasso BL, Giglio RV, Bivona G, Gambino CM, Cortegiani A, et al. Monocyte distribution width as a biomarker of sepsis in the intensive care unit: A pilot study. Ann Clin Biochem. 2021; 58 (1):70–3. Epub 2020/10/20. https://doi.org/10.1177/0004563220970447 PMID: 33074719.

36. Agor J, Ozaltin OY, Ivy JS, Capan M, Arnold R, Romero S. The value of missing information in severity of illness score development. J Biomed Inform. 2019; 97:103255. Epub 2019/07/28. https://doi.org/10.1016/j.jbi.2019.103255 PMID: 31349049.